MindRank gets USFDA clearance of IND application for MDR-001 for treatment of Type 2 diabetes
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation
The scheme is subject to statutory and regulatory approvals as may be necessary.
36.4% of patients with diabetic neuropathic pain in 2021 were completely treatment refractory and would benefit from new treatment options.
Global pharmaceutical company having a surgical business concept incepted in Dubai
Positive opinions based on significant survival benefit
AUR101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients
India now has 648 medical colleges in 2022 with a whopping 96% increase in the number of Government Medical Colleges (GMC) alone and a 42% increase in the private sector, since 2014
Ayúdame3D has become a leading social entity in social technology.
Subscribe To Our Newsletter & Stay Updated